A NOVEL therapeutic approach targeting the cytokine A Proliferation-Inducing Ligand (APRIL) may significantly reduce proteinuria and disease activity in patients with IgA nephropathy, according to ...

Vertex Pharmaceuticals has a rolling biologics license application with the FDA for povetaciceptin IgA nephropathy. With new data from RAINIER, the biotech expects to complete its submission by the ...

Vertex reported a phase 3 win for its kidney disease prospect povetacicept, meeting analyst expectations and firing the starting gun on a race to the FDA that could result in an accelerated approval ...

Povetacicept significantly reduced proteinuria in patients with IgA nephropathy in the RAINIER trial, supporting an upcoming FDA submission.

Jay N. Yepuri, MD, MS, FACG, is a board-certified gastroenterologist and member of the Digestive Health Associates of Texas Board of Directors and Executive Committee. A liver function test checks how ...

Leerink Global Healthcare Conference 2026 March 10, 2026 1:00 PM EDTCompany ParticipantsUptal Patel - Chief Medical ...

Oppenheimer 36th Annual Healthcare Life Sciences Conference February 26, 2026 1:20 PM ESTCompany ParticipantsTom Frohlich ...

Prioritizing three key, late-stage clinical programs including Molecular Degrader of Extracellular Proteins (MoDETM) and Targeted Removal of Aberrant ...

A look at the biologics, gene therapies, and vaccines most likely to reshape care —and manufacturing—in the year ahead.